Dargie HJ (May 2001). “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial”. 《Lancet》 357 (9266): 1385–1390. doi:10.1016/s0140-6736(00)04560-8. PMID11356434. S2CID1840228.
Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, 외. (June 2015). “Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention”. 《The American Journal of Cardiology》 115 (11): 1529–1538. doi:10.1016/j.amjcard.2015.02.057. PMID25862157.
Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR (December 2002). “Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma”. 《The Journal of Heart and Lung Transplantation》 21 (12): 1290–5. doi:10.1016/s1053-2498(02)00459-x. PMID12490274.
Lo GH, Chen WC, Wang HM, Yu HC (November 2012). “Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding”. 《Journal of Gastroenterology and Hepatology》 27 (11): 1681–7. doi:10.1111/j.1440-1746.2012.07244.x. PMID22849337. S2CID23494154.
World Health Organization (2021). 《World Health Organization model list of essential medicines: 22nd list (2021)》. Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Dargie HJ (May 2001). “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial”. 《Lancet》 357 (9266): 1385–1390. doi:10.1016/s0140-6736(00)04560-8. PMID11356434. S2CID1840228.
Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, 외. (June 2015). “Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention”. 《The American Journal of Cardiology》 115 (11): 1529–1538. doi:10.1016/j.amjcard.2015.02.057. PMID25862157.
Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR (December 2002). “Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma”. 《The Journal of Heart and Lung Transplantation》 21 (12): 1290–5. doi:10.1016/s1053-2498(02)00459-x. PMID12490274.
Lo GH, Chen WC, Wang HM, Yu HC (November 2012). “Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding”. 《Journal of Gastroenterology and Hepatology》 27 (11): 1681–7. doi:10.1111/j.1440-1746.2012.07244.x. PMID22849337. S2CID23494154.
Dargie HJ (May 2001). “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial”. 《Lancet》 357 (9266): 1385–1390. doi:10.1016/s0140-6736(00)04560-8. PMID11356434. S2CID1840228.
Lo GH, Chen WC, Wang HM, Yu HC (November 2012). “Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding”. 《Journal of Gastroenterology and Hepatology》 27 (11): 1681–7. doi:10.1111/j.1440-1746.2012.07244.x. PMID22849337. S2CID23494154.